64Cu-Dotatate

DRUG4 trials

Sponsors

Rigshospitalet, Radiomedix, Inc., Rigshospitalet, Denmark, University of Wisconsin, Madison

Conditions

GEP-NETNeuroendocrine CarcinomaNeuroendocrine Carcinoma MetastaticNeuroendocrine TumorsNeuroendocrine neoplasmsSomatostatin Receptor-positive Neuroendocrine Tumor

Phase 1

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

RecruitingNCT06122610

University of Wisconsin, MadisonNeuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor

Start: 2025-03-07End: 2026-06-01Target: 10Updated: 2026-03-19

Phase 2

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Rigshospitalet, DenmarkGEP-NET, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma Metastatic +1

Start: 2023-01-17End: 2026-01-01Target: 200Updated: 2023-11-22

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients with Neuroendocrine Neoplasms

RecruitingCTIS2024-516156-18-00

RigshospitaletNeuroendocrine neoplasms

Start: 2023-01-17Target: 200Updated: 2024-08-20

Phase 3

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

CompletedNCT03673943

Radiomedix, Inc.Neuroendocrine Tumors

Start: 2018-08-23End: 2019-08-07Updated: 2022-12-22